Under fire for abandoning a plan to allow Medicare to negotiate drug pricing, Democrats in the Senate have reached an agreement that could see the policy reintroduced in the Biden administr
Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people with rare diseases and cancers – but they could also mean healthcare systems
Fears that President Trump will push through policies that will damage healthcare and science are generating active resistance from the scientific community in the US and beyond.
Loopholes which allow companies to exploit generic drug prices are being closed down in the UK - but the US may have to rely on peer pressure for the meantime.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.